Showing 5431-5440 of 5909 results for "".
- ProtoKinetix: Tests Show AAGP-Preserved and Enabled Retinal Cells to Mature Without Compromise after 5-Month Milestonehttps://modernod.com/news/protokinetix-tests-show-aagp-preserved-and-enabled-retinal-cells-to-mature-without-compromise-after-5-month-milestone/2476822/ProtoKinetix updated shareholders regarding ongoing third stage testing of retinal cell replacement therapy at the University of British Columbia. As previously reported, the company demonstrated the ability of AAGP to protect transplanted cells in a preclinical experimental model of retinal dege
- Quantel Medical Announces Acquisition of Optotek Medicalhttps://modernod.com/news/quantel-medical-announces-acquisition-of-optotek-medical/2476821/Quantel Medical announced that it is acquiring ophthalmic medical device maker Optotek Medical. This acquisition comes after a long collaboration between the two companies through the development and supply of devices
- Iconic Therapeutics Signs Ophthalmology Option Agreement With Novartishttps://modernod.com/news/iconic-therapeutics-signs-ophthalmology-option-agreement-with-novartis/2476818/Iconic Therapeutics announced that the company has signed an agreement with Novartis in which Novartis will have an option on Iconic’s ophthalmology program, now in preclinical development. Novartis made an upfront payment and an equity investment in Iconic. The details of investment were not dis
- Trump Administration to Appeal Ruling Barring Proposed Drug Price Disclosure Policyhttps://modernod.com/news/trump-administration-to-appeal-ruling-barring-proposed-drug-price-disclosure-policy/2476816/The administration of US President Donald Trump plans to appeal a recent federal court decision striking down a Department of
- Nidek Launches the Mirante Scanning Laser Ophthalmoscopehttps://modernod.com/news/nidek-launches-the-mirante-scanning-laser-ophthalmoscope/2479546/Nidek has announced the launch of the Mirante Scanning Laser Ophthalmoscope. The Mirante is a multimodal fundus imaging platform that combines high definition SLO and OCT with ultra widefield imaging. The multimodal p
- Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Wet AMD and DMEhttps://modernod.com/news/aerie-pharmaceuticals-initiates-first-in-human-clinical-trial-of-ar-13503-sustained-release-intravitreal-implant-in-patients-with-wet-amd-and-dme/2476812/Aerie Pharmaceuticals announced the commencement of patient dosing in a first-in-human clinical trial of AR-13503 Sustained Release (SR) implant in patients with neovascular age-related macular degeneration (AMD) or diabetic macular edema (DME). This multi-arm, 24-week study (AR-13503-CS20
- Trial of Tele-Ophthalmology System at Regional Health Board in Scotland Shows Promising Resultshttps://modernod.com/news/trial-of-tele-ophthalmology-system-at-regional-health-board-in-scotland-shows-promising-results/2476808/Researchers at the University of Strathclyde and NHS Forth Valley in Scotland have developed a tele-ophthalmology system that, according to recent data, has reduced the need for follow-up appointments and waiting times for treatments in over 50% of cases, according to a
- Prevent Blindness Creates New “Diabetes and the Eyes” Educational Resourcehttps://modernod.com/news/prevent-blindness-creates-new-diabetes-and-the-eyes-educational-resource/2476805/To educate consumers on one of the leading causes of vision loss and blindness, Prevent Blindness has created a new resource, the “
- ProQR Announces Clearance of IND to Start Clinical Trial of QR-1123 in Patients with Autosomal Dominant Retinitis Pigmentosa (adRP)https://modernod.com/news/proqr-announces-clearance-of-ind-to-start-clinical-trial-of-qr-1123-in-patients-with-autosomal-dominant-retinitis-pigmentosa-adrp/2476802/ProQR Therapeutics announced that the FDA has cleared the investigational new drug (IND) application for QR-1123. ProQR plans to start enrolling patients in a phase 1/2 trial for QR-1123 in 2019. QR-1123 is a first-in-class investigational oligonucleotide designed to address the underlying
- OcuNexus Therapeutics Making Progress with Inflammasome Inhibition Program in Ophthalmic Diseasehttps://modernod.com/news/ocunexus-therapeutics-making-significant-progress-with-inflammasome-inhibition-program-in-ophthalmic-disease/2479550/OcuNexus Therapeutics announced that it has strengthened its board of directors with the addition of Rajiv Shukla, who has deep experience in the investment and commercial aspects of the pharmaceutical industry. OcuNexus Therapeutics is a clinical stage biotechnology company develop